← Leaderboards
Kaalak Reddy
State University Of New York At Albany
$925,778
Attributed
$2,565,876
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $917.3K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,565,876 · 2
By mechanism
R01$2,142,960 · 1
R21$422,916 · 1
Top collaborators
- John A Berglund9 shared
- Masayuki Nakamori9 shared
- Gabriele Fuchs1 shared
Most similar at State University Of New York At Albany
Same institution · by research overlap
- Masayuki Nakamori$714,320
- Arun Richard Chandrasekaran$1,782,963
- Gabriele Fuchs$365,958
Others in their field
Other Rising Stars on “Family”
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Alaina J Harkness · Current Innovation, Nfp$13,724,091
- Maximilian Haeussler · University Of California Santa Cruz$12,592,563
- Michael George Natchus · Emory University$10,548,554
- John Alam · Eip Pharma, Inc.$10,411,018
- April Carson · University Of Mississippi Med Ctr$9,022,104
Research focus
FamilyBiologyMyotonic DystrophyGenetic TranscriptionSmall Molecule TherapeuticsRna SplicingMolecularMuscular DystrophiesProteinsDesignSmall MoleculeRna ProcessingSeriesTranscriptPathway InteractionsCell LinePolycyclic CompoundsComplexIn VivoIn VitroPathogenesisPathologyRna-Binding ProteinsTranscriptome Sequencing
Grant awards (10)
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$425,205
R01 · FY2025 · NS
Functional consequences of ITPase deficiency and the impact of inosine misincorporation into the transcriptome$422,916
R21 · FY2025 · HD · contact PI
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$69,192
R01 · FY2025 · NS
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$465,688
R01 · FY2024 · NS
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$69,192
R01 · FY2024 · NS
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$13,694
R01 · FY2024 · NS
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$488,445
R01 · FY2023 · NS
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$55,928
R01 · FY2023 · NS
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$45,776
R01 · FY2023 · NS
Design, synthesis and efficacy of new small molecule therapeutics to impede myotonic dystrophy$509,840
R01 · FY2022 · NS